Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TE-8214 in Healthy Volunteers
NCT06372652Phase 1Completed
- Sponsor
- Immunwork
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acromegaly comparing SAD Cohort (TE-8214) with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-related adverse events and 4 more. Started Jun 2024; status: completed.
02
Drugs
TE-8214
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT06372652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372652.